HRGN · Harvard Apparatus Regenerative Technology, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Because these resources are not expected to fund the Company's operations for at least 12 months from the date the financial statements are issued, substantial doubt exists about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-21 | He Junli |
Director, CEO |
Award↑
Filing footnotes — Nonqualified Stock Option (right to buy), time-based tranche (Direct)
Subject to the Reporting Person's continued employment through each applicable vesting date, the time-based portion of the nonqualified stock option vests and becomes exercisable as follows: 100,000 shares vest upon signing of the applicable award agreement, representing vesting for the six-month period from March 1, 2026 through August 31, 2026, subject to the Reporting Person's continued employment through the date of signing. Thereafter, 16,667 shares vest on the first day of each calendar month commencing September 1, 2026, subject to the Reporting Person's continued employment with the Issuer through each applicable vesting date; provided that the final monthly installment will be adjusted as necessary so that no more than 600,000 shares vest under the time-based tranche. |
Nonqualified Stock Option (right to buy), time-based tranche
|
600,000 |
| 2026-07-21 | He Junli |
Director, CEO |
Award↑
Filing footnotes — Nonqualified Stock Option (right to buy), performance-based (Direct)
Subject to the Reporting Person's continued employment through the applicable vesting date, the performance-based portion of the nonqualified stock option vests and becomes exercisable in four milestone tranches as follows: (i) 250,000 shares upon the closing of a sale of a controlling stake in the Issuer or the listing of its common stock on a national securities exchange (Nasdaq or NYSE), whichever occurs first, following the grant date; (ii) 125,000 shares if, at any time following the Issuer's initial public offering or the listing of its common stock on a national securities exchange, the volume-weighted average price of the Issuer's common stock equals or exceeds two times (2.0x) the initial public offering price or initial listing price, or such fixed target as may be established by the Compensation Committee, e.g., $3.00 per share, for twenty (20) consecutive trading days; (iii) 125,000 shares upon the first date on which the Issuer has raised at least an additional $10,000,000 |
Nonqualified Stock Option (right to buy), performance-based
|
600,000 |
| 2025-11-25 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from November 25, 2025 to November 26, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
3,000 |
| 2025-09-30 | He Junli |
Director, CEO |
Buy↑
|
Common Stock
|
300 |
| 2025-09-02 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 2, 2025 to September 22, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
11,225 |
| 2025-08-21 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 21, 2025 to August 29, 2025. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
4,050 |
| 2025-06-27 | GREEN DAVID |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Sanchez Herman |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | Sanchez Herman |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Packard Ronald J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Chen Jing |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Zhang Mao |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Shmerling James E. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | Chen Jing |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | Li Ting |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Li Ting |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | Shmerling James E. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2025, December 27, 2025, March 27, 2026 and June 27, 2026. |
Stock Option (right to buy)
|
18,590 |
| 2025-06-27 | Zhang Mao |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | GREEN DAVID |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2025-06-27 | Packard Ronald J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2025, September 30, 2025 and December 31, 2025. |
Stock Option (right to buy)
|
15,227 |
| 2024-12-24 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 24, 2024 to December 30, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
2,299 |
| 2024-09-03 | Zhang Mao |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on December 3, 2024, March 3, 2025, June 3, 2025 and September 3, 2025. |
Stock Option (right to buy)
|
7,198 |
| 2024-08-27 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 27, 2024 to September 6, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
5,101 |
| 2024-07-31 | DST Capital LLC |
10% Owner |
Other↑
Filing footnotes — Warrants (right to buy) (Direct)
These warrants were transferred by the Reporting Person to two unaffiliated persons. |
Warrants (right to buy)
|
140,000 |
| 2024-07-31 | DST Capital LLC |
10% Owner |
Other↑
Filing footnotes — Warrants (right to buy) (Direct)
These warrants were transferred by the Reporting Person to one unaffiliated person. |
Warrants (right to buy)
|
25,000 |
| 2024-07-08 | DST Capital LLC |
10% Owner |
Other↑
Filing footnotes — Warrants (right to buy) (Direct)
These warrants were transferred by the Reporting Person to two unaffiliated persons. |
Warrants (right to buy)
|
50,000 |
| 2024-06-27 | Li Ting |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | Chen Jing |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | Sanchez Herman |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | Packard Ronald J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | Shmerling James E. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-27 | Li Ting |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-27 | Sanchez Herman |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-27 | Packard Ronald J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-27 | Shmerling James E. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | GREEN DAVID |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on September 27, 2024, December 27, 2024, March 27, 2025 and June 27, 2025. |
Stock Option (right to buy)
|
10,204 |
| 2024-06-27 | GREEN DAVID |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-27 | Chen Jing |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, June 30, 2024, September 30, 2024 and December 31, 2024. |
Stock Option (right to buy)
|
8,215 |
| 2024-06-21 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from June 21, 2024 to June 27, 2024. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
1,600 |
| 2024-01-11 | He Junli |
Director, CEO |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
Subject to continued employment or service through the applicable vesting dates, up to 220,640 shall vest in two increments, each for 110,320 shares, each such vesting subject to certain performance milestones set by the Board of Directors of the Issuer. |
Stock Option (right to buy)
|
220,640 |
| 2023-12-27 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 27, 2023 to December 29, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
2,700 |
| 2023-12-14 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 14, 2023 to December 15, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
900 |
| 2023-12-06 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from December 6, 2023 to December 8, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
1,500 |
| 2023-09-11 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from September 11, 2023 to September 15, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
1,500 |
| 2023-08-28 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 28, 2023 to September 1, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
3,400 |
| 2023-08-21 | Shmerling James E. |
Director |
Buy↑
|
Common Stock
|
6,864 |
| 2023-08-18 | He Junli |
Director, CEO |
Buy↑
Filing footnotes — Common Stock (Direct)
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions from August 18, 2023 to August 25, 2023. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. |
Common Stock
|
8,000 |
| 2023-07-26 | Chen Jing |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, September 30, 2023, December 31, 2023 and March 31, 2024. |
Stock Option (right to buy)
|
5,819 |
| 2023-07-26 | Shmerling James E. |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option was granted in lieu of cash compensation otherwise payable to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on the grant date, September 30, 2023, December 31, 2023 and March 31, 2024. |
Stock Option (right to buy)
|
5,819 |
| 2023-07-26 | Packard Ronald J |
Director |
Award↑
Filing footnotes — Stock Option (right to buy) (Direct)
This Stock Option represents the annual equity grant to the Reporting Person, as a non-employee director of the Issuer, and will vest in four equal installments on October 26, 2023, January 26, 2024, April 26, 2024 and July 26, 2024. |
Stock Option (right to buy)
|
7,269 |